The observation status for Prostatype Genomics AB is removed
On February 14, 2025, the shares in Prostatype Genomics AB (the “Company”) were given observation status with reference to material adverse uncertainty in respect of the issuer’s financial position.
On July 27, 2026, the Company disclosed the outcome in a rights issue of units.
With reference to the above, Nasdaq Stockholm AB decides that the observation status for the Company’s shares shall be removed.
| Company name: | Prostatype Genomics AB |
| Short name: | PROGEN |
| ISIN code: | SE0023261532 |
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.